Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review

Benzinga2021-09-01

The FDA has accepted Teva Pharmaceutical Industries Ltd and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia. TV-46000/mdc-IRM is a risperidone extended-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

SFern
2021-09-01
SFern
Good
- SFern:
  Lol
ZhaoYingying
2021-09-01
ZhaoYingying
Like
- atsc:
  Done
Blackk
2021-09-01
Blackk
Like and comment
DorisTanMIL
2021-09-01
DorisTanMIL
Pls like
Sysy
2021-09-01
Sysy
L &c
- DorisTanMIL:
  Hi
WannaBluffy
2021-09-01
WannaBluffy
Like
- WannaBluffy:
  Comment
- canoboi:
  like

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128019873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-01 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128019873","market":"us","top_or_hot":-1,"title":"Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review","media":"Benzinga","content":"<div>\n<p>The FDA has accepted Teva Pharmaceutical Industries Ltd  and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia.\nTV-46000/mdc-IRM is a risperidone extended-...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-01 20:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has accepted Teva Pharmaceutical Industries Ltd  and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia.\nTV-46000/mdc-IRM is a risperidone extended-...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review","article_id":"1128019873","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128019873","pubTimestamp":1630499831,"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"The FDA has accepted Teva Pharmaceutical Industries Ltd  and MedinCell's marketing application seeki","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"Teva-Medincell的精神分裂症治疗候选药正在FDA审查中","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":0.9},"content_text":"The FDA has accepted Teva Pharmaceutical Industries Ltd  and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia.\nTV-46000/mdc-IRM is a risperidone extended-release injectable suspension for subcutaneous use.\nThe acceptance is based on Phase 3 data from two pivotal studies. Results will be shared at future scientific conferences and in peer-reviewed publications.\nTeva will continue to lead the clinical development and regulatory process and be responsible for the commercialization of this candidate treatment, with MedinCell eligible for development milestones, royalties on net sales, and future commercial milestones.\nTeva is also conducting another Phase 3 study designed to evaluate the long-term safety, tolerability, and effectiveness of TV-46000 subcutaneously administered for up to 56 weeks in 331 schizophrenia patients.\nThe primary endpoint is the frequency of all adverse events, including serious adverse events. This study is ongoing; interim results align with the findings of the RISE study.\nPrice Action: TEVA shares are up 0.64% at $9.48 during the premarket session on the last check Wednesday.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":816235446,"gmtCreate":1630503300485,"gmtModify":1676530322133,"author":{"id":"3582938826092533","authorId":"3582938826092533","name":"SFern","avatar":"https://static.tigerbbs.com/81a61c88544234a53cc63054a8f769b1","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/816235446","repostId":1128019873,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5718865,"gmtCreate":1630503306325,"gmtModify":1663233233134,"authorId":3582938826092533,"author":{"id":3582938826092533,"authorId":3582938826092533,"name":"SFern","avatar":"https://static.tigerbbs.com/81a61c88544234a53cc63054a8f769b1","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816235446,"type":1,"supId":0,"prevId":0,"content":"Lol","text":"Lol","html":"Lol"}],"langContent":"EN"},{"id":816645790,"gmtCreate":1630500773210,"gmtModify":1676530320964,"author":{"id":"3577155247763320","authorId":"3577155247763320","name":"ZhaoYingying","avatar":"https://static.tigerbbs.com/b86f603c032bb4185ad17dff4bc5cb95","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/816645790","repostId":1128019873,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5718631,"gmtCreate":1630502072247,"gmtModify":1663233231230,"authorId":3562791266647459,"author":{"id":3562791266647459,"authorId":3562791266647459,"name":"atsc","avatar":"https://static.tigerbbs.com/9ec47b1c36e59ba1ef8caac8ab619319","vip":1,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816645790,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":816648357,"gmtCreate":1630500302579,"gmtModify":1676530320872,"author":{"id":"3572770726668540","authorId":"3572770726668540","name":"Blackk","avatar":"https://static.tigerbbs.com/93d9bfa23cdea8af3308e34dedf35d9e","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816648357","repostId":1128019873,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":816649705,"gmtCreate":1630500160707,"gmtModify":1676530320819,"author":{"id":"3582942873418844","authorId":"3582942873418844","name":"DorisTanMIL","avatar":"https://static.tigerbbs.com/75b9822f6cf594977f9894a9b2c5a4cf","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816649705","repostId":1128019873,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":816640142,"gmtCreate":1630499987886,"gmtModify":1676530320786,"author":{"id":"3581726174893746","authorId":"3581726174893746","name":"Sysy","avatar":"https://static.tigerbbs.com/f89400ba2f20ed80423858c0f6a3d8ee","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"L &amp;c","listText":"L &amp;c","text":"L &c","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/816640142","repostId":1128019873,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5718371,"gmtCreate":1630500155338,"gmtModify":1663233233937,"authorId":3582942873418844,"author":{"id":3582942873418844,"authorId":3582942873418844,"name":"DorisTanMIL","avatar":"https://static.tigerbbs.com/75b9822f6cf594977f9894a9b2c5a4cf","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816640142,"type":1,"supId":0,"prevId":0,"content":"Hi","text":"Hi","html":"Hi"}],"langContent":"EN"},{"id":816657271,"gmtCreate":1630499937293,"gmtModify":1676530320752,"author":{"id":"3586986998667843","authorId":"3586986998667843","name":"WannaBluffy","avatar":"https://static.tigerbbs.com/1dd14463a45a95644b65d2bd68777ecd","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/816657271","repostId":1128019873,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5718329,"gmtCreate":1630499948993,"gmtModify":1663233228847,"authorId":3586986998667843,"author":{"id":3586986998667843,"authorId":3586986998667843,"name":"WannaBluffy","avatar":"https://static.tigerbbs.com/1dd14463a45a95644b65d2bd68777ecd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816657271,"type":1,"supId":0,"prevId":0,"content":"<u>Comment</u>","text":"<u>Comment</u>","html":"<u>Comment</u>"},{"id":5718345,"gmtCreate":1630499995296,"gmtModify":1663233228827,"authorId":3554895157968981,"author":{"id":3554895157968981,"authorId":3554895157968981,"name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816657271,"type":1,"supId":0,"prevId":0,"content":"like","text":"like","html":"like"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":60,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128019873"}